Sun Pharma partner's skin cancer drug demonstrates efficacy against skin cancer

Sun Pharma's partner, Philogen, has reported positive results in late-stage clinical trials for its new drug, Nidlegy, which is used to treat skin cancers. In the trial, Nidlegy demonstrated a statistically significant improvement in recurrence-free survival for patients with resectable melanoma. The study compared Nidlegy followed by surgery with surgery alone. The treatment arm showed a reduction in the hazard risk ratio, and treatment-related adverse events were reported to be benign and manageable. Nidlegy is also being developed for the treatment of other types of skin cancers.